Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Develops New Phase IIa Alzheimer\u2019s Trial Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Hauck Aufh\u00e4user Lampe Privatbank AG","pharmaFlowCategory":"D","amount":"$26.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer\u2122s Disease to Proceed at Highest Investigated Dose","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Vivoryon Therapeutics

    Menu

    Vivoryon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vivoryon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimers Disease

              Details:

              PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivoryon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision

              Details:

              PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivoryon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzh...

              Details:

              PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivoryon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

              Details:

              Vivoryon intends to use the net proceeds to accelerate the ongoing clinical development of its lead product candidate PQ912 (varoglutamstat), currently in Phase 2 in Europe and the United States for the treatment of patients with Alzheimer’s disease.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hauck Aufhäuser Lampe Privatbank AG

              Deal Size: $26.8 million Upfront Cash: Undisclosed

              Deal Type: Private Placement May 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivoryon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease

              Details:

              PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivoryon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O...

              Details:

              Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nordic Bioscience

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivoryon Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivoryon Develops New Phase IIa Alzheimer’s Trial Design

              Details:

              Vivoryon and the Alzheimer’s Disease Cooperative Study have developed a new trial design for Phase 2a Alzheimer’s trial in the US as a stage gate to Phase 2b. Vivoryon’s lead candidate, PQ912, got approval of the International Nonproprietary Name (INN), varoglutamstat.

              Lead Product(s): Varoglutamstat

              Therapeutic Area: Neurology Product Name: PQ912

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY